Health · 3 views
Investigational immunotherapy nearly doubles overall survival compared with docetaxel in advanced squamous NSCLC
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody…
Summary
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart, compared with 10.0 months for patients receiving docetaxel, according to updated findings from stage 1 of the Phase III PRESERVE-003 trial.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Dengue‑carrying mosquitoes expand their reach into new territories—including FloridaContinue reading
- EARLY RELEASE: Notes from the Field: The First 100 Days of Five Ebola Outbreaks - Democratic Republic of the Congo, Uganda, and West Africa, 2007-2026Continue reading
- Retinal scans may flag atrial fibrillation four years before diagnosisContinue reading
- Social media is promoting harmful attitudes towards sun exposure | LetterContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow